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 Unlocking reactivity of TrpB: a general biocatalytic platform for syn-
thesis of tryptophan analogs 
David K. Romney, Javier Murciano-Calles, Jöri E. Wehrmüller, Frances H. Arnold* 
Division of Chemistry and Chemical Engineering 210-41, California Institute of Technology, 1200 East California Boule-
vard, Pasadena, California 91125, United States   
KEYWORDS biocatalysis, tryptophan synthase, noncanonical amino acids, natural products 
ABSTRACT: Derivatives of the amino acid tryptophan (Trp) serve as precursors for the chemical and biological synthesis of com-
plex molecules with a wide range of biological properties. Trp analogs are also valuable as building blocks for medicinal chemistry 
and as tools for chemical biology. While the enantioselective synthesis of Trp analogs is often lengthy and requires the use of pro-
tecting groups, enzymes have the potential to synthesize such products in fewer steps and with the pristine chemo- and stereoselec-
tivity that is a hallmark of biocatalysis. The enzyme TrpB is especially attractive because it can form Trp analogs directly from 
serine (Ser) and the corresponding indole analog. However, many potentially useful substrates, including bulky or electron-
deficient indoles, are poorly accepted. We have applied directed evolution to TrpB from Pyrococcus furiosus and Thermotoga 
maritima to generate a suite of catalysts for the synthesis of previously intractable Trp analogs. For the most challenging substrates, 
such as nitroindoles, the key to improving activity lay in the mutation of a universally conserved and mechanistically important 
residue, E104. The new catalysts express at high levels (>200 mg/L of E. coli culture) and can be purified by heat treatment; they 
can operate up to 75 °C (where solubility is enhanced) and can synthesize enantiopure tryptophan analogs substituted at the 4-, 5-, 
6-, and 7-positions, using Ser and readily available indole analogs as starting materials. Spectroscopic analysis shows that many of 
the activating mutations suppress the decomposition of the active electrophilic intermediate, an amino-acrylate, which aids in un-
locking the synthetic potential of TrpB. 
INTRODUCTION 
To develop functional complex molecules, synthetic chem-
ists must have access to a broad range of chemical building 
blocks. These include noncanonical amino acids, which are 
not found in proteins, but are often encountered as intermedi-
ates in biosynthesis. Derivatives of tryptophan (Trp) occupy a 
distinguished position in the echelons of noncanonical amino 
acids, because they are biosynthetic precursors to compounds 
that possess diverse activities,
1-2
 including anticancer, antibi-
otic, immunosuppressant, antifungal, and phytotoxic proper-
ties. Tryptophan analogs have also been used as starting mate-
rials for chemical syntheses
3-9
 as well as probes for chemical 
biology.
10-13
 Therefore, efficient methods to synthesize Trp 
analogs are needed. 
Enzymes have emerged as powerful new tools for chemical 
synthesis, catalyzing reactions with unrivaled rate acceleration 
and exceptional selectivity.
14-16
 While nature has created a vast 
repertoire of enzymes that modify Trp through a plethora of 
transformations, including nitration, halogenation, and alkyla-
tion (Figure 1a),
2
 only a few of these enzymes have been in-
vestigated for use in synthetic chemistry.
17-22
 Furthermore, this 
approach is limited because the synthesis of each Trp analog 
requires a different enzyme. We wished to develop an alter-
nate biocatalytic approach, in which a single catalyst platform 
would provide direct access to any Trp analog from readily 
available starting materials.  
 
Figure 1. Synthesis of Trp analogs. (a) Examples of biosynthetic 
intermediates derived from Trp. (b) Previous synthetic methods 
using enzymes.9, 23-24 (c) Alternative biocatalytic route based on 
TrpB. Ac = acetyl.   
Enzymes such as acylases
9, 23
 and transaminases
24
 (Figure 
1b) have been applied to synthesis of tryptophan analogs, but 
in these approaches, the majority of the product must be as-
sembled in advance, with the enzymes mostly serving to set 
the stereochemistry at the end. Many methods, such as those 
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 that use esterases, rely on kinetic resolution, which limits the 
maximum theoretical yield of product to 50%. A notable ex-
ception is the use of tryptophan synthase (TrpS), which can 
assemble Trp analogs from L-serine (Ser) and the correspond-
ing indole analog with retention of enantiopurity (Figure 
1c).
25-30
 
While the chemical synthesis of Trp analogs is challenging, 
methods to prepare indole analogs abound.
31-32
 Thus, the TrpS 
methodology has the potential to provide direct access to a 
wide array of products. Unfortunately, the activity of wild-
type TrpS is highly sensitive to the electronic and steric prop-
erties of the substrates. Protein-engineering techniques such as 
directed evolution are an effective means to unlock new func-
tion, such as high activity with non-native substrates. Howev-
er, directed evolution has scarcely been applied to TrpS, partly 
because this protein is a complex of two distinct proteins: an 
α-subunit (TrpA) and a β-subunit (TrpB). Although only TrpB 
is involved in the proposed synthesis of Trp analogs, TrpA is 
an allosteric actuator, whose absence severely attenuates TrpB 
activity. Recently, we developed variants of TrpB from Pyro-
coccus furiosus
33-34
 and other organisms,
35
 which do not re-
quire their TrpA partner proteins to achieve full activity. We 
therefore wished to expand this initial set of stand-alone vari-
ants into a general platform for the synthesis of Trp analogs, 
especially those on which TrpS is poorly active.  
In an initial survey of substrates, our attention was immedi-
ately drawn to 4-substituted indoles, since this substitution 
pattern is present in natural products, but was poorly reactive 
in previous studies with TrpB. In particular, we focused on 4-
nitroindole (Scheme 1) because the nitro substituent not only 
creates a steric impediment to substrate binding, but also with-
draws electron density from the indole moiety. Since the in-
dole is a nucleophile in this reaction manifold, electron-
withdrawing substituents are intrinsically deactivating. The 
compound 4-nitroTrp is a biosynthetic and chemical precursor 
to thaxtomin A, a potentially useful agrochemical (Chart 1).
4, 
36-38
 Additionally, 4-nitroTrp is a chemical precursor to the 
tumor-promoter indolactam V.
5
 However, the chemical syn-
thesis of enantiopure 4-nitroTrp is complex,
4
 and the natural 
enzymatic route is not amenable to application on a large 
scale.
39
 Furthermore, we hypothesized that the evolutionary 
journey toward an optimized TrpB catalyst for 4-nitroTrp 
would yield catalysts with improvements for other challenging 
substrates. 
Scheme 1. Test reaction for optimization of TrpB 
 
Chart 1. Natural products synthesized from 4-nitroTrp 
 
 
 
RESULTS 
Initial activity of stand-alone variants toward 4-
nitroindole. TrpB from P. furiosus and Thermotoga maritima 
are optimal parents for directed evolution, due to their high 
thermostability.
40
 We therefore tested the wild-type proteins 
(PfTrpB and TmTrpB), as well as the already-generated stand-
alone variants for the production of 4-nitroTrp. As expected, 
the wild-type enzymes exhibited only trace activity (Figure 
S1). In addition, many of the variants formed a significant 
amount of a side product, which is putatively isotryptophan 1 
(Figure 2). Fortunately, one variant, Pf2B9, provided 18% 
conversion of 4-nitroindole to 4-nitroTrp. Notably, this vari-
ant, which has eight mutations from wild-type PfTrpB, was 
initially evolved for activity with indole and threonine (Thr).
34
 
Thus, the fortuitous improvement for 4-nitroindole and Ser 
lent support to our hypothesis that optimizing a catalyst for 
production of 4-nitroTrp would provide simultaneous gains for 
other substrates. 
We looked to the TrpB catalytic mechanism in order to 
identify what might be limiting conversion of 4-nitroindole. 
TrpB uses the cofactor pyridoxal phosphate (PLP), which is 
covalently bound to a lysine residue in the active site (Figure 
2a, intermediate I). The lysine is displaced by Ser (intermedi-
ate II), which then undergoes α-deprotonation (intermediate 
III) and β-elimination to generate the active electrophile, ami-
no-acrylate IV. Ideally, this would be attacked by the nucleo-
philic substrate, such as 4-nitroindole, to form the Trp product.  
 
Figure 2. Putative pathways for reaction with 4-nitroindole. (a) 
Catalytic cycle for formation of 4-nitroTrp. (b) Enzymatic de-
composition of Ser. (c) Competitive formation of isotryptophan 1.  
We observed that increasing catalyst loading had a negligi-
ble effect on production of 4-nitroTrp (Figure S2a), but that 
the Ser was almost completely consumed at the end of the 
reaction period (Figure S3). By contrast, production of 4-
nitroTrp was improved by addition of excess Ser (Figure S2b). 
These observations are consistent with the well-known side 
reaction in which the amino-acrylate is ejected from the PLP 
cofactor and undergoes hydrolytic decomposition to pyruvate 
(Figure 2b).
41
 In addition, we sometimes observed formation 
of what we believe is isotryptophan 1 (Figure 2c and Figure 
S4a), in which 4-nitroindole adds to the amino-acrylate 
through the endocyclic nitrogen atom (N1) rather than the 
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 desired carbon atom (C3). While this reaction appears to be 
reversible, it undoubtedly slows the desired reaction. Our goal 
was to engineer a TrpB that would rapidly and quantitatively 
convert equimolar amounts of 4-nitroindole and Ser into 4-
nitroTrp with perfect regio- and enantioselectivity. 
Effects of active-site mutagenesis. Lacking a high-
throughput assay for production of 4-nitroTrp, we initially 
focused on small site-saturation mutagenesis libraries that 
could be screened by high-performance liquid chromatography 
(HPLC). Previously, an X-ray crystal structure was obtained 
of TrpB from Salmonella enterica (SeTrpB) with both the 
amino-acrylate and benzimidazole, an indole mimic, bound in 
the active site (PDB ID: 4HPX).
42
 Although PfTrpB and 
SeTrpB have modest sequence identity (59%), we previously 
observed a high degree of structural similarity between struc-
tures of PfTrpB and TrpB from Salmonella typhimurium 
(StTrpB), which also have only 59% sequence identity.
33
 We 
therefore constructed a homology model with the sequence of 
PfTrpB and placed 4-nitroindole into the binding pose neces-
sary to achieve C–C bond formation, in the hope of identifying 
steric clashes that could be alleviated by mutations (Figure 3). 
Unfortunately, the model suggested that the nitro group was 
clashing with the protein main chain as well as with the PLP 
cofactor (Figure 3a). Nonetheless, we identified four residues 
whose side chains extended into the indole-binding pocket: 
L161, I165, V187, and Y301 (Figure 3b). The side-chain of 
E104 also occupies the active site, but this residue is thought 
to bind indole through the NH moiety, thereby promoting at-
tack from C3. Since this residue is universally conserved in 
TrpB homologs, and the enzymes already suffered from poor 
regioselectivity with 4-nitroindole, we elected to avoid muta-
genesis at this position. We hypothesized that mutation at the 
other four positions could create space for 4-nitroindole to 
bind in an alternative pose that relieved the steric clashes but 
still allowed for attack of the amino-acrylate.  
 
Figure 3. Model of 4-nitroindole (yellow) and the amino-acrylate 
in the active site of PfTrpB (see Section 8.13 of Supporting In-
formation). (a) Nitro group clashes with the protein backbone 
(green) and the PLP cofactor (purple). (b) Alternative view show-
ing side-chains extending in to the active site and hydrogen bond 
with E104. 
Mutations of the targeted residues were almost uniformly 
deleterious, with the exception of L161V, which boosted the 
yield of 4-nitroTrp to 25%. While this improvement is modest, 
the mutation also suppressed formation of the side-product 
(Figure S4b). It is worth noting that although the side-chain of 
valine is indeed smaller than that of leucine, mutation of this 
position to alanine is deleterious. Thus, the effects of active-
site mutagenesis cannot be rationalized by simple models 
based on sterics.  
Screening of random-mutagenesis libraries. Having 
failed to achieve significant gains in activity from active-site 
mutagenesis, we hoped that random mutagenesis would pro-
vide beneficial mutations elsewhere in the protein scaffold. 
However, such libraries often have low frequencies of benefi-
cial mutations, the result of which is that large numbers (hun-
dreds to thousands) of variants must be screened to find im-
provements. In our initial generation of the stand-alone TrpB 
catalysts, we had exploited the spectroscopic shift between 
indole and tryptophan to screen initial rates in a high-
throughput manner.
33
 However, 4-nitroindole proved to be 
substantially more difficult. Unlike indole, 4-nitroindole has 
minimal solubility in water, even with 5% dimethyl sulfoxide 
(DMSO) as a co-solvent. Furthermore, the initial rate of even 
the most evolved catalyst was too low to screen reliably, a 
problem compounded by the fact that the spectral difference 
between 4-nitroindole and 4-nitroTrp is much smaller than that 
of indole and tryptophan. Instead, we chose to exploit the sol-
ubility differences between 4-nitroindole and 4-nitroTrp. Spe-
cifically, the reactions were run in aqueous conditions with 5% 
DMSO as a co-solvent, then the residual starting material was 
extracted in an organic solvent (ethyl acetate). The amount of 
4-nitroTrp was determined by measuring the absorption of the 
aqueous phase in the visible spectrum.  
Using the newly developed assay, we tested a random-
mutagenesis library, generated by error-prone polymerase 
chain reaction, and identified a variant, with mutations M139L 
and L212P, that almost doubled the HPLC yield of 4-nitroTrp 
to 49% (Figure 4). We next tested a library which randomly 
recombined those two mutations and N166D, a beneficial mu-
tation identified in a separate study.
35
 We also varied the ac-
tive-site L161V mutation, since its effect had been compara-
tively minor. Indeed, in the best variant from this library 
(Pf5G8), the active-site mutation had reverted back to leucine 
and the other three mutations were retained. This variant 
formed 4-nitroTrp in 60% HPLC yield from equimolar 
amounts of 4-nitroindole and Ser. 
 
Figure 4. Evolutionary progression in production of 4-nitroTrp. 
Mutations in bold were added in the corresponding round of mu-
tagenesis and screening. Dashed lines denote a new round of ran-
dom mutagenesis. The horizontal axis indicates catalyst designa-
tions. See Section 8.7 of the Supporting Information for experi-
mental details. 
Energized by that success, we generated another random-
mutagenesis library with Pf5G8 as the parent protein. From 
this library, two mutations were found (I183F and V186A) 
that increased HPLC yield slightly, to ~70%. The most signifi-
cant improvement, however, came from a variant bearing the 
mutation E104G, which increased HPLC yield to ~87% and 
eviscerated the earlier supposition that an H-bonding interac-
tion with 4-nitroindole and the side-chain of E104 would pro-
mote the reaction. We then screened a recombination library 
and found that the E104G mutation recombined with I183F 
and V186A to produce 4-nitroTrp in 91% HPLC yield. Final-
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 ly, we screened a site-saturation library at position 104 and 
found that glycine at this position was optimal, with Ala yield-
ing similar, but slightly inferior results (Figure S5). 
Optimization toward isomeric nitroindoles. With the new 
catalysts in hand, we wished to see if the evolution had created 
specificity for 4-nitroindole, or if it had improved activity for 
other substrates as well. We therefore tested catalysts Pf5G8 
and Pf2A6 with 5-, 6-, and 7-nitroindole (Chart 2). Gratifying-
ly, Pf5G8 showed improvement for all substrates compared to 
Pf2B9, forming all isomeric nitrotryptophans in about 60% 
HPLC yield (Table 1, entries 1 and 2). Enzyme Pf2A6, on the 
other hand, showed almost quantitative conversion of 7-
nitroindole to the corresponding nitroTrp, but low activity 
with 5- and 6-nitroindole (Table 1, entry 3). Because we had 
previously identified catalysts that exhibited moderate activity 
with these substrates, we wondered if a subset of the mutations 
from Pf2A6 would further activate them for 5- and 6-
nitroindole. The mutations associated with each catalyst des-
ignation are summarized in Table 2. 
Chart 2. Nitro substitution at other positions  
 
Table 1. Optimizing catalysts for other nitroindole isomers 
Entry Catalysta 
HPLC yield of nitroTrp (%)b 
4-nitro 5-nitro 6-nitro 7-nitro 
1 Pf2B9 18 8 17 29 
2 Pf5G8 60 64 64 64 
3 Pf2A6 91 5 26 >99 
4 Tm2F3 76   
5 Tm2F3 I184F 86   
6 Pf2B9 I165F Y301H  66  
7 Pf0A9  86  
8 Pf0A9 E104G  91  
aSee Table 2 for catalyst designations. bReactions used equimo-
lar amounts of nitroindole and Ser. See Section 8.7 of the Sup-
porting Information for experimental details.  
Previously, engineered variants of TmTrpB had shown 
higher activity with 5-substituted indoles than their PfTrpB 
homologs.
35
 Additionally, it was observed that if certain bene-
ficial mutations in PfTrpB variants were transferred to the 
corresponding positions in TmTrpB, then the activating effects 
were also transferred.
35
 We therefore constructed a library in 
which the mutations of Pf2A6 were randomly recombined at 
the corresponding positions in TmTrpB. Screening for activity 
with 5-nitroindole revealed two variants that outperformed all 
previous catalysts in the production of 5-nitrotryptophan. The 
first, Tm2F3, contained five mutations that were originally 
found in Pf2B9 plus all three mutations from Pf5G8; this vari-
ant formed 5-nitrotryptophan in 76% HPLC yield (Table 1, 
entry 4). The second variant was identical, but also contained 
one of the mutations found in Pf2A6 (I184F, according to 
numbering in T. maritima). This mutation gave a further boost 
in yield to 86% (Table 1, entry 5). 
To improve activity with 6-nitroindole, we returned to the 
parent enzyme Pf2B9 and the active-site mutagenesis libraries 
from the beginning of this study. Although these libraries had 
not yielded significant gains for 4-nitroindole, we hypothe-
sized that 6-nitroindole might respond differently, due to its 
distinct shape. Indeed, while no mutation at L161 was activat-
ing, the single mutations I165F and Y301H were both benefi-
cial (Figure S6). Ultimately, the best variant contained both of 
these mutations and formed 6-nitroTrp in 66% HPLC yield 
(Table 1, entry 6). A random recombination library of the mu-
tations from Pf2A6 revealed a new variant, Pf0A9, bearing 
mutations M139L and N166D, which increased the yield to 
86% (Table 1, entry 7). Surprisingly, the mutation E104G also 
enhanced activity, albeit modestly, to 91% yield (Table 1, 
entry 8). 
Table 2. Catalyst designations and associated mutations 
Designation 
Species of 
origin Mutations 
Pf2B9a P. furiosus I16V, E17G, I68V, F95L, T292S, 
F274S, T321A, V384A 
Pf5G8 P. furiosus Pf2B9 + M139L, N166D, L212P 
Pf2A6 P. furiosus Pf5G8 + E104G 
Pf0A9 P. furiosus Pf2B9 + M139L, I165F, N166D, 
Y301H 
Tm2F3 T. maritima P19G, I69V, K96L, P140L, N167D, 
L213P, T292S 
aVariant from ref 34. 
Substrate scope of catalyst panel. To evaluate their gener-
ality and synthetic utility, we tested the newly optimized cata-
lysts against a range of indole substrates (Table 3). We were 
pleased to find that the catalysts accepted essentially every 
indole analog that we tested, often forming the corresponding 
tryptophan product in excellent yield. For preparative reac-
tions, however, we chose to focus on halogenated and elec-
tron-deficient indoles, since historically these have been the 
most challenging.  
Despite the tremendous improvement in 4-nitrotryptophan 
production, the catalysts still struggled with substituents at the 
4-position. With 4-nitroindole, Pf2A6 can achieve ~5000 turn-
overs, but the reaction seems to slow considerably toward the 
end (Figure S7). As a result, a higher catalyst loading is re-
quired to achieve the high conversion observed in the catalyst 
evolution (Table 3, entry 1). Fortunately, the catalysts are ex-
pressed at high levels (>200 mg/L of E. coli culture) and can 
be used as heat-treated lysate, without additional protein puri-
fication. As a result, we were easily able to synthesize over a 
gram of 4-nitrotryptophan (73% isolated yield) using the pro-
tein from a 1-L bacterial culture (see Section 9.4 of Supporting 
Information). The enzymes could also form 4-
fluorotryptophan in excellent yield (Table 3, entry 2), as well 
as 4-bromo- and 4-cyanotryptophan, albeit with modest activi-
ty (Table 3, entries 3 and 4, respectively). With indole-4-
boronic acid, however, no product was detected (Table 3, en-
try 5). Strangely, the optimal catalyst was different for almost 
every substrate, further underscoring the idiosyncrasy of 4-
substitution. 
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 As with 4-nitroindole, the reaction with 5-nitroindole 
slowed toward the end (Figure S8). Nonetheless, 5-
nitrotryptophan could be obtained in 88% yield with a higher 
catalyst loading (Table 3, entry 6). Good results were also 
obtained with other electron-withdrawing substituents, such as 
nitrile, carboxamide, and boronate (Table 3, entries 7–9). No-
tably, we also observed promising activity with 5-iodo- and 5-
trifluoromethylindole (Table 3, entries 10 and 11), on which 
previous catalysts had shown no detectable activity.   
The 6-substituted indoles proved to be the best behaved and 
most predictable series of substrates. At this position, high 
yields were obtained with the nitro substituent (Table 3, entry 
12), as well as halo substituents (Table 3, entries 13 and 14) 
and other electron-withdrawing substituents like nitrile (Table 
3, entry 15) and boronate (Table 3, entry 16). Unlike with the 
4- and 5-positions, the two enzymes evolved for activity with 
6-nitroindole were always among the best catalysts. 
Excellent activity was also observed with 7-substituted in-
doles, though the optimal catalyst was hard to predict. While 
7-nitroindole and 7-cyanoindole favored Pf2A6 (Table 3, en-
tries 17 and 18), Pf0A9 gave optimal activity for 7-chloro- and 
7-iodoindole (Table 3, entries 19 and 20). Strangely, 7-
bromoindole gave poorer results than the other haloindoles, 
though 7-bromotryptophan could be formed in modest yield 
with catalyst Pf5G8 (Table 3, entry 21). No product was de-
tected with indole-7-boronic acid (Table 3, entry 22).  
Finally, we explored the production of tryptophan analogs 
with multiple substituents. This capability is important both 
because poly-substituted Trp derivatives are precursors to 
many natural products and because poly-halogenated arenes 
are prevalent in bioactive compounds in general.
22, 43
 Fortu-
nately, the 5,6-dichloro and 5-bromo-7-fluoro products could 
be obtained in good yields using Pf5G8 and Tm2F3 I184F, 
respectively (Table 3, entries 23 and 24). The bulkier 5-
chloro-7-iodo product was also accessible, though in low yield 
(Table 3, entry 25). 
Kinetic effects of the mutations. Our hypothesis at the out-
set of this project had been that the conversion of slowly react-
ing substrates like 4-nitroindole was limited by competing 
hydrolysis of the amino-acrylate intermediate. Increasing the 
conversion at the reaction endpoint, therefore, would require 
accelerating the nucleophilic attack of the substrate, such as 
through binding in the active site, and increasing the persis-
tence of the amino-acrylate intermediate. While the poor solu-
bility of 4-nitroindole frustrated our ability to measure Mich-
aelis-Menten kinetics, we could approximate the initial rate of 
4-nitroTrp production under the reaction conditions by meas-
uring conversion at short reaction times (Table 4). In addition, 
we measured the rate of Ser deamination by incubating the 
enzymes with Ser, in the absence of a nucleophilic substrate, 
and measuring the production of pyruvate. Finally, we meas-
ured the initial rate of tryptophan production under the same 
reaction conditions that we used for 4-nitroTrp.   
Table 4. Initial rates throughout evolution
a
 
Entry Catalyst 
Initial turnover frequency (min–1) 
to 4-nitroTrp to pyruvate to Trp 
1 PfTrpB – 24 ± 1.0 19 ± 1.2 
2 Pf2B9 1.25 ± 0.07 12.2 ± 0.5 60.9 ± 0.16 
3 Pf5G8 1.8 ± 0.12 2.0 ± 0.2 9.9 ± 0.5 
4 Pf5G8 E104G 3.5 ± 0.2 0.9 ± 0.12 7.03 ± 0.07 
5 Pf2A6 7.0 ± 0.3 1.4 ± 0.10 17.6 ± 0.3 
aSee Sections 8.10, 8.11, and 8.12 of Supporting Information. 
Of all the catalysts, wild-type TrpB has the highest deami-
nation rate, even higher than the rate of Trp production, and 
produces negligible levels of 4-nitroTrp (Table 4, entry 1). 
The variant Pf2B9, which produces Trp at a rate similar to the 
Table 3. Tryptophan analogs produced by catalyst panel
a
 
Entry Substrate  R Catalyst 
Isolated 
yield (%) 
1 
 
 NO2 Pf2A6 95
b 
2  F Tm2F3 97 
3  Br Tm2F3 72 
4  CN Tm2F3 I184F 41b 
5  B(OH)2  ND 
6  NO2 Tm2F3 I184F 88
b 
7  CN Tm2F3 79 
8  CONH2 Tm2F3
 77 
9  B(OH)2 Pf0A9 37 
10  I Pf0A9 74b 
11  CF3 Pf2A6 19
b, c 
aReactions used 0.02 mol % catalyst loading (maximum 5000 
turnovers) and 1.1 equiv Ser relative to indole substrate. bCatalyst 
loading was 0.1 mol % (maximum 1000 turnovers). cReaction gives 
alkylation at nitrogen. ND, not detected. 
Entry Substrate  R Catalyst 
Isolated 
yield (%) 
12 
 
 NO2 Pf0A9 E104G 91 
13  Cl Pf0A9 98 
14  Br Pf0A9 97 
15  CN Pf0A9 99 
16  B(OH)2 Pf0A9 49 
17 
 
 NO2 Pf2A6 98 
18  CN Pf2A6 98 
19  Cl Pf0A9 99 
20  I Pf0A9 91 
21  Br Pf5G8 53 
22  B(OH)2  ND 
23 
 
 
5,6-Cl2 Pf5G8 87 
24 
 
 5-Br-7-F Tm2F3 I184F 56 
25  5-Cl-7-I Tm2F3 10 
 
 
Page 5 of 9
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 wild-type complex,
33
 shows both an increase in the rate of 4-
nitroTrp production and a decrease in the rate of Ser deamina-
tion (Table 4, entry 2). The next variant, Pf5G8, exhibits only 
a modest increase in the rate of 4-nitroTrp production, but a 
six-fold decrease in the rate of Ser deamination and an almost 
three-fold decrease in the rate of Trp production (Table 4, 
entry 3). The mutation E104G changes both 4-nitroTrp pro-
duction and Ser deamination in approximately equal measure, 
but surprisingly exerts only a minor influence on Trp produc-
tion (Table 4, entry 4). Finally, the addition of I183F and 
V186A actually increases the rate of Ser deamination, but 
increases the rate of the desired reaction even more (Table 4, 
entry 5). These last two mutations also return Trp production 
to the level of Pf5G8. 
DISCUSSION 
Organic synthesis using TrpB. In the synthesis of non-
canonical amino acids, installation of the chiral amino-acid 
moiety is often the most challenging part, due to the stereo-
chemistry at the α-carbon. Many synthetic approaches, there-
fore, involve the modification of existing amino acids, in 
which the stereochemistry is already established. Even then, 
the reactivity of the amine and carboxylate functional groups 
can interfere with many synthetic methodologies, and thus 
require protecting groups. In contrast, TrpB uses unprotected 
Ser as the amino acid donor and forms the products in almost 
perfect enantiopurity. The reaction is operationally straight-
forward (simply add substrates and enzyme to buffer and ap-
ply heat), and the products can often be purified by precipita-
tion directly from the reaction mixture, or alternatively by a 
facile chromatographic separation. Due to their high expres-
sion level and thermostability, the enzymes can be obtained 
easily and handled without special precautions. Furthermore, 
the active electrophilic species, the amino-acrylate, is formed 
and persists only in the enzyme active site, thus minimizing 
the burden of product purification. 
While the range of products formed by TrpB was previously 
restricted to a narrow set of Trp analogs, the results of this 
study demonstrate that the product scope can be greatly ex-
panded through protein engineering. More generally, they 
show how TrpB can mediate efficient reactions with excep-
tionally weak nucleophiles like 4-nitroindole, which is elec-
tronically deactivated, sterically hindered, and poorly soluble. 
It is likely, therefore, that the product scope of TrpB can be 
expanded even further to include many types of noncanonical 
amino acids, in addition to Trp analogs.  
Role of M139 and N166 in open/close transition. TrpB is 
well known to adopt discrete conformational states, including 
a fully open state, which is inactive but permits substrate entry 
and product release, and a fully closed state, which promotes 
amino-acrylate formation and nucleophilic addition but blocks 
access to the active site. Previous studies have also shown that 
stabilization of the closed state is associated with a decreased 
rate of Ser deamination.
44
 Since M139L and N166D lie out-
side the active site, we hypothesized that their beneficial ef-
fect, which is mainly to suppress Ser deamination, might arise 
from stabilization of the closed state. While the evolved vari-
ants from this study did not form diffracting crystals, we pre-
viously obtained structures of wild-type PfTrpB in the open 
and partially closed states.
33
 A comparison of the structures 
immediately reveals that the side-chain of N166, which is mu-
tated to aspartate in Pf5G8, forms a hydrogen bond in the 
closed state with the side-chain of H275, which undergoes a 
rotameric switch that closes the active site (Figure 5). It is 
therefore plausible that strengthening of this interaction with 
the more basic aspartate would stabilize the closed state of the 
enzyme. Interestingly, the parent enzyme, Pf2B9, also has the 
mutation F274S, which is adjacent to H275, thus highlighting 
the importance of mutations in this region to activity. The 
effect of mutating M139 to L is more difficult to rationalize, 
but this residue is adjacent to the domain that mediates com-
munication between TrpA and TrpB in the wild-type complex 
and which is known to undergo a large displacement in the 
transition from open to closed. Thus, it is plausible that a mu-
tation at this position would influence the transition between 
the open and closed states.  
 
Figure 5. Overlaid crystal structures of PfTrpB (PDB ID: 5DVZ) 
in the open state (cyan) and partially closed state (PDB ID: 
5DW0, red) showing the side-chain motion of N166, and H275. 
Influence of mutations on the active site. Unlike the pre-
vious stages of evolution, all the mutations from the final 
round (E104G, I183F, and V186A) occur at positions in the 
enzyme active site. In the case of I183 and V186, the side-
chains do not interact directly with the substrates, nor do they 
undergo significant movement during the transition from the 
open to closed state. Thus, the beneficial effects of the muta-
tions are likely due to subtle reshaping of the active site to 
accommodate the size of 4-nitroindole and bind the substrate 
in a more reactive conformation. This is consistent with the 
observation that addition of these two mutations greatly in-
creases the rate of 4-nitroTrp production while exerting little 
effect on the rate of Ser deamination (Table 4, entries 4 and 5).  
Various roles have been assigned to the side-chain of E104, 
including activation of the Ser β-hydroxyl group as a leaving 
group, as well as binding and activation of the indole nucleo-
phile (see Figure 2, intermediates II and III).
45
 Indeed, studies 
of TrpS from S. typhimurium (StTrpS) showed that mutation 
of the corresponding residue to alanine
46
 eliminated activity 
with indole and Ser.
47
 However, this activity was rescued by 
the introduction of certain monovalent cations, such as Cs
+
, 
indicating that neither of the aforementioned roles of E104 are 
essential. It therefore seems that its most significant role is in 
modulating the transition of the enzyme to the closed state. 
This was supported by the observation that increasing concen-
trations of CsCl shifted the catalytic steady state of the variant 
away from the external aldimine (Figure 2, intermediate II) 
toward the amino-acrylate as the major species, a trend that is 
a hallmark of closed-state stabilization. By contrast, Pf5G8 
and the E104G variants exhibit similar rates of Trp production, 
and the amino-acrylate predominates in the steady state of 
both variants (Figure S9). In fact, the E104G mutation appears 
to stabilize the closed state, as inferred from the two-fold de-
crease in deamination rate (Table 4, entries 3 and 4). Thus, it 
may be that the other mutations in Pf5G8 have changed the 
function of E104, or that the role of this residue is different in 
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 PfTrpB and StTrpB. Studies are ongoing to elucidate the role 
and generality of this mysterious mutation.  
Impact on substrate specificity. It is often thought that 
evolving an enzyme for activity with a particular substrate 
ultimately imparts specificity toward that substrate as well. 
This study, however, shows that directed evolution toward a 
particularly challenging substrate can be an effective strategy 
to improve activity for non-native substrates in general. In-
deed, the intermediate catalyst, Pf5G8, exhibited concomitant 
increases in activity for all four nitroindoles (Table 1). While 
this enzyme was rarely the optimal catalyst, as indicated by its 
infrequent appearance in Table 3, it exhibited good activity for 
most substrates (see Table S1). The additional mutations in the 
most evolved enzyme, Pf2A6, appeared to lower the substrate 
generality, but nonetheless improved activity for multiple sub-
strates, such as 7-nitroindole, in addition to the test substrate, 
4-nitroindole. Furthermore, the mutations of Pf2A6 served as 
the basis to generate all other catalysts in this study, demon-
strating that although a specific catalyst may not be optimal 
for all substrates, the mutations are activating in multiple con-
texts. 
Our approach of creating a small panel of general catalysts 
likely succeeded because the conversion of most non-native 
substrates was limited by a single enzymatic process, Ser hy-
drolysis. Thus, directed evolution could select for mutations 
that curtailed Ser hydrolysis independently of a specific sub-
strate. This is consistent with the results of Table 4, in which 
the rate of Ser deamination decreases even in the absence of a 
nucleophilic substrate. While these specific circumstances 
may not apply to all enzyme engineering problems, we would 
expect directed evolution to provide a general benefit where 
side activities that limit enzyme performance can be targeted 
independently. 
CONCLUSION   
By evolving for activity with nitroindoles, we have devel-
oped a panel of TrpB-derived biocatalysts that exhibit good to 
excellent activity with mono- and disubstituted indoles. The 
substrate scope includes indoles bearing electron-withdrawing 
groups, such as nitro and cyano, which are fundamentally de-
activating in this reaction manifold. These results showcase 
the potency of the amino-acrylate as an electrophile, as well as 
the ability of the active site to protect the amino-acrylate from 
degradation, while promoting reactions with even the most 
stubborn nucleophiles. These qualities make TrpB catalysis a 
versatile and easy-to-use platform for the production of valua-
ble synthetic building blocks. 
The results also demonstrate that the universally conserved 
E104 residue is a key target for mutagenesis to improve activi-
ty with non-native substrates. This may provide a promising 
starting point to adapt TrpB for the synthesis of new product 
classes. More generally, this demonstrates how mutations at 
residues that seem crucial can in fact be the most valuable 
handles for tuning activity with new substrates.  
ASSOCIATED CONTENT 
Supporting Information 
The Supporting Information is available free of charge on the 
ACS Publications website. 
 
Additional figures and experimental procedures (PDF) 
 
NMR spectra (PDF) 
AUTHOR INFORMATION 
ORCID David K. Romney: 0000-0003-0498-7597 
ORCID Javier Murciano-Calles: 0000-0002-8667-1651 
Corresponding Author 
* E-mail: frances@cheme.caltech.edu.  
ORCID Frances H. Arnold: 0000-0002-4027-364X  
Funding Sources 
This work was funded by the Jacobs Institute for Molecular Med-
icine (Caltech) and the Gordon and Betty Moore Foundation 
(through the Caltech Programmable Molecular Technology Initia-
tive). D.K.R. was supported by a Ruth Kirschstein NIH Postdoc-
toral Fellowship (F32GM117635) and J.M.-C. was supported by a 
fellowship from the Alfonso Martín Escudero Foundation.  
Notes 
The contents of this paper are the subject of a patent application 
submitted by Caltech, and some authors are entitled to a royalty 
on revenues arising from that patent. 
ACKNOWLEDGMENT  
The authors thank Dr. Sabine Brinkmann-Chen for advice on 
developing the screening assay, Dr. Andrew Buller for helpful 
discussions and comments on the manuscript, and Elliot Mackrell 
for assistance in screening the catalyst libraries. 
REFERENCES 
1. Jordan, P. A.; Moore, B. S. Cell Chem. Bio. 2016, 23, 1504-
1514. 
2. Alkhalaf, Lona M.; Ryan, Katherine S. Chem. Biol. 2015, 22, 
317-328. 
3. Feng, Y.; Holte, D.; Zoller, J.; Umemiya, S.; Simke, L. R.; 
Baran, P. S. J. Am. Chem. Soc. 2015, 137, 10160-10163. 
4. Zhang, H.; Ning, X.; Hang, H.; Ru, X.; Li, H.; Li, Y.; Wang, L.; 
Zhang, X.; Yu, S.; Qiao, Y.; Wang, X.; Wang, P. G. Org. Lett. 2013, 
15, 5670-5673. 
5. Xu, Z.; Zhang, F.; Zhang, L.; Jia, Y. Org. Bio. Chem. 2011, 9, 
2512-2517. 
6. Ma, B.; Banerjee, B.; Litvinov, D. N.; He, L.; Castle, S. L. J. 
Am. Chem. Soc. 2010, 132, 1159-1171. 
7. Artman, G. D.; Grubbs, A. W.; Williams, R. M. J. Am. Chem. 
Soc. 2007, 129, 6336-6342. 
8. Baran, P. S.; Guerrero, C. A.; Ambhaikar, N. B.; Hafensteiner, 
B. D. Angew. Chem., Int. Ed. 2005, 44, 606-609. 
9. Ley, S. V.; Priour, A.; Heusser, C. Org. Lett. 2002, 4, 711-714. 
10. Talukder, P.; Chen, S.; Roy, B.; Yakovchuk, P.; Spiering, M. 
M.; Alam, M. P.; Madathil, M. M.; Bhattacharya, C.; Benkovic, S. J.; 
Hecht, S. M. Biochem. 2015, 54, 7457-7469. 
11. Roy, A. D.; Goss, R. J. M.; Wagner, G. K.; Winn, M. Chem. 
Comm. 2008, 4831-4833. 
12. Zhong, W.; Gallivan, J. P.; Zhang, Y.; Li, L.; Lester, H. A.; 
Dougherty, D. A. Proc. Nat. Acad. Sci. 1998, 95, 12088-12093. 
13. Hilaire, M. R.; Ahmed, I. A.; Lin, C.-W.; Jo, H.; DeGrado, W. 
F.; Gai, F. Proc. Nat. Acad. Sci. 2017, 114, 6005-6009. 
14. Choi, J.-M.; Han, S.-S.; Kim, H.-S. Biotechnol. Adv. 2015, 33, 
1443-1454. 
15. Nestl, B. M.; Hammer, S. C.; Nebel, B. A.; Hauer, B. Angew. 
Chem., Int. Ed. 2014, 53, 3070-3095. 
16. Wohlgemuth, R. Curr. Opin. Biotech. 2010, 21, 713-724. 
17. Payne, J. T.; Andorfer, M. C.; Lewis, J. C. Angew. Chem., Int. 
Ed. 2013, 52, 5271-5274. 
18. Durak, L. J.; Payne, J. T.; Lewis, J. C. ACS Catal. 2016, 6, 
1451-1454. 
Page 7 of 9
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19. Shepherd, S. A.; Menon, B. R. K.; Fisk, H.; Struck, A.-W.; 
Levy, C.; Leys, D.; Micklefield, J. Chembiochem 2016, 17, 821-824. 
20. Latham, J.; Henry, J.-M.; Sharif, H. H.; Menon, B. R. K.; 
Shepherd, S. A.; Greaney, M. F.; Micklefield, J. Nat. Comm. 2016, 7, 
11873. 
21. Dodani, S. C.; Kiss, G.; Cahn, J. K. B.; Su, Y.; Pande, V. S.; 
Arnold, F. H. Nat. Chem. 2016, 8, 419-425. 
22. Smith, D. R. M.; Uria, A. R.; Helfrich, E. J. N.; Milbredt, D.; 
van Pée, K.-H.; Piel, J.; Goss, R. J. M. ACS Chem. Biol. 2017, 12, 
1281-1287. 
23. Blaser, G.; Sanderson, J. M.; Batsanov, A. S.; Howard, J. Tet. 
Lett. 2008, 49, 2795-2798. 
24. Baldwin, J. E.; Dyer, R. L.; Ng, S. C.; Pratt, A. J.; Russell, M. 
A. Tet. Lett. 1987, 28, 3745-3746. 
25. Corr, M. J.; Smith, D. R. M.; Goss, R. J. M. Tetrahedron 2016, 
72, 7306-7310. 
26. Smith, D. R. M.; Willemse, T.; Gkotsi, D. S.; Schepens, W.; 
Maes, B. U. W.; Ballet, S.; Goss, R. J. M. Org. Lett. 2014, 16, 2622-
2625. 
27. Perni, S.; Hackett, L.; Goss, R. J.; Simmons, M. J.; Overton, T. 
W. AMB Express 2013, 3, 66. 
28. Winn, M.; Roy, A. D.; Grüschow, S.; Parameswaran, R. S.; 
Goss, R. J. M. Bioorg. Med. Chem. Lett. 2008, 18, 4508-4510. 
29. Goss, R. J. M.; Newill, P. L. A. Chem. Comm. 2006, 4924. 
30. Lee, M.; Phillips, R. S. Bioorg. Med. Chem. Lett. 1992, 2, 
1563-1564. 
31. Guo, T.; Huang, F.; Yu, L.; Yu, Z. Tet. Lett. 2015, 56, 296-302. 
32. Inman, M.; Moody, C. J. Chem. Sci. 2013, 4, 29-41. 
33. Buller, A. R.; Brinkmann-Chen, S.; Romney, D. K.; Herger, 
M.; Murciano-Calles, J.; Arnold, F. H. Proc. Nat. Acad. Sci. 2015, 
112, 14599-14604. 
34. Herger, M.; van Roye, P.; Romney, D. K.; Brinkmann-Chen, 
S.; Buller, A. R.; Arnold, F. H. J. Am. Chem. Soc. 2016, 138, 8388-
8391. 
35. Murciano-Calles, J.; Romney, D. K.; Brinkmann-Chen, S.; 
Buller, A. R.; Arnold, F. H. Angew. Chem., Int. Ed. 2016, 55, 11577-
11581. 
36. Zhang, H.; Wang, Q.; Ning, X.; Hang, H.; Ma, J.; Yang, X.; 
Lu, X.; Zhang, J.; Li, Y.; Niu, C.; Song, H.; Wang, X.; Wang, P. G. J. 
Agric. Food Chem. 2015, 63, 3734-3741. 
37. Bourgault, J. P.; Maddirala, A. R.; Andreana, P. R. Org. Bio. 
Chem. 2014, 12, 8125-8127. 
38. King, R. R.; Calhoun, L. A. Phytochemistry 2009, 70, 833-841. 
39. Barry, S. M.; Kers, J. A.; Johnson, E. G.; Song, L.; Aston, P. 
R.; Patel, B.; Krasnoff, S. B.; Crane, B. R.; Gibson, D. M.; Loria, R.; 
Challis, G. L. Nat. Chem. Biol. 2012, 8, 814-816. 
40. Bloom, J. D.; Labthavikul, S. T.; Otey, C. R.; Arnold, F. H. 
Proc. Nat. Acad. Sci. 2006, 103, 5869-5874. 
41. Crawford, I. P.; Ito, J. Proc. Nat. Acad. Sci. 1964, 51, 390-397. 
42. Niks, D.; Hilario, E.; Dierkers, A.; Ngo, H.; Borchardt, D.; 
Neubauer, T. J.; Fan, L.; Mueller, L. J.; Dunn, M. F. Biochem. 2013, 
52, 6396-6411. 
43. Agarwal, V.; Miles, Z. D.; Winter, J. M.; Eustáquio, A. S.; El 
Gamal, A. A.; Moore, B. S. Chem. Rev. 2017, 117, 5619-5674. 
44. Fan, Y. X.; McPhie, P.; Miles, E. W. Biochem. 2000, 39, 4692-
4703. 
45. Dunn, M. F. Arch. Biochem. Biophys. 2012, 519, 154-166. 
46. E109A in the numbering of S. typhimurium. 
47. Ruvinov, S. B.; Ahmed, S. A.; McPhie, P.; Miles, E. W. J. Bio. 
Chem. 1995, 270, 17333-17338. 
 
 
 
Page 8 of 9
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
9
 
Table of contents only 
Page 9 of 9
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
